Alvotech gets marketing approval in Japan for three new biosimilars
Source: SeekingAlpha
2025-09-19 07:53:58 ET
More on Alvotech
- Alvotech (ALVO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
- Alvotech 2025 Q2 - Results - Earnings Call Presentation
- Alvotech (ALVO) Q2 2025 Earnings Call Transcript
- Alvotech, Advanz Pharma get EU nod for Eylea biosimilar
- Alvotech targets 50% U.S. Humira biosimilar market share by year-end as Q2 product revenues rise 77%
Read the full article on Seeking Alpha
For further details see:
Alvotech gets marketing approval in Japan for three new biosimilars
Alvotech
NASDAQ: ALVO
ALVO Trading
-6.23% G/L:
$3.01 Last:
679,105 Volume:
$3.23 Open:
ALVO Latest News
May 11, 2026 04:30:00 am
Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility
ALVO Stock Data
$1,569,389,520
107,654,085
N/A
30
N/A
Pharmaceuticals
Healthcare
LU
Luxembourg
